Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 clinical trial of intravitreally injected ADX-248 for the treatment of geographic atrophy, a sight-threatening retinal disease

Next Previous
Trial Profile

Phase 1/2 clinical trial of intravitreally injected ADX-248 for the treatment of geographic atrophy, a sight-threatening retinal disease

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADX 248 (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 04 Jan 2024 According to Aldeyra Therapeutics media release, an IND application of ADX-248 is expected to be submitted in 2024.
  • 28 Feb 2023 New trial record
  • 23 Feb 2023 According to Aldeyra Therapeutics media release, pending completion of the IND requirements this trial is expected to initiate in the second half of 2023 or early 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top